Introduction: In this article, non -alcoholic fatty liver disease (NAFLD) is discussed in detail. The epidemiology of NAFLD nonalcoholic steatohepatitis and the relationship of NAPLD with type 2 diabetes mellitus insulinemic resistance are broadly discussed. NAFLD incorporates histologically and clinically different non-alcoholic entities fatty liver (NAFL, steatosis hepatis) and steatohepatitis (NASH characterized by hepatocyte ballooning and lobular inflammation + fibrosis) might progress to cirrhosis and rarely to hepatocellular cancer. Type 2 diabetes mellitus (T2DM), insulin resistance (IR), obesity and NAFLD are particularly closely related. Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) commonly exist together.

Age is major determinant of NAFLD. As Body mass index and waist-to-hip ratio were not independently associated with nonalcoholic fatty liver diseases in our study, suggesting that obesity might also be effects of insulin resistance. Insulin resistance leads to foot accumulation in hepatocytes by lipolysis and hyperinsulinemia.

Objective: The objective of the study was to find out the association of NAFLD with insulinemic status in type 2 DM subjects.

Results: The present data leads to the suggestion that there is a strong association between insulin resistance and NAFLD. However, the question of whether hyperinsulinemia or insulin resistance is the primary disorder of NAFLD remains unangered. Further studies are needed to elucidate interrelationship between NAFLD, metabolic syndrome and insulin resistance.

Keywords: Cirrhosis, insulin resistance, metabolic syndrome, nonalcoholic fatty liver, type 2 diabetes mellitus.

1. American Heart Association (2004). Heart disease and stroke statistical update. Dallas,Texas, USA.
2. Beckman JA, Creager MA, Libby P (2002). Diabetes and atherosclerosis. JAMA 287: 2570-81.
3. Gavin JR III, Alberti KGMM, Davidson MB (1997). Report of the export committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20: 1183-97.
4. Boden G (1997). Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 536.
5. Taylor SI, Accili D, Imai Y (1994). Perspectives in diabetes: Insulin resistance or insulin deficiency, which is the primary cause of Type 2 DM? Diabetes 43: 735-9.
6. AGA (2002). American Gastroenterological Association technical review on nonalcoholic fatty liver disease. Gastroenterology 123: 1705-25.
7. Williams R (2006). Global challenges in liver disease. Hepatology 44: 521-6
8. Kelley D, Goodpaster B, Storlien L (2002). Muscle triglyceride and insulin resistance. Annu Rev Nutr 22: 325-46.
9. Smith S, Ravussin E (2002). Emerging paradigms for understanding fatness and diabetes risk. Curr Diab Rep 2: 223-30.
10. Angulo P (2002). Nonalcoholic fatty liver disease. N Engl J Med 346:1221-31.
11. Clark JM, Brancati FL, Diehl AM (2003): The prevalence and aetiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98: 960–7.
12. Rocha R, Cotrim HP, Carvello FM, Sequira AC, Brega H, Freitas LA (2005). Body mass index and waist circumference in nonalcoholic fatty liver disease. J Hum Nutr Dietet 18: 365-70.
13. Salgodo Jr. W, Santos JS, Sankarankutty AK, Castro ESilva OD (2006). Non-alcoholic fatty liver disease and obesity. Acta Cir Bras 21: 72-8.

Dr Azmeri Alam

Associate Professor, Department of Biochemistry, Green Life Medical College, Dhaka, Bangladesh